Pfizer’s Ongoing Study on COVID-19 and Influenza: What Investors Need to Know

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.

Pfizer Inc., in collaboration with CVS Caremark, is conducting a study titled ‘Patient-Reported Outcomes Associated With COVID-19 and Influenza: A Prospective Survey Study on Outpatient Symptomatic Adults With Test-Confirmed Illness in the United States.’ The study aims to understand the health-related outcomes and symptoms of individuals with COVID-19 or influenza, as well as the effects of COVID-19 vaccines on these patients. This research is significant as it will provide insights into the patient experience and the impact of vaccination on symptomatic individuals.

The intervention being tested is the Pfizer BioNTech COVID-19 vaccine, which is intended to assess its effects on individuals with test-confirmed COVID-19 illness. The study also includes a cohort of participants with influenza, although no specific intervention is being tested for this group.

This is an observational, prospective cohort study. Participants are not randomly assigned, and the study does not involve any masking. The primary purpose is to collect and evaluate patient-reported outcomes over a six-month period, focusing on symptoms and health-related quality of life.

The study began on January 31, 2022, and is currently recruiting participants. The last update was submitted on June 25, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.

For investors, this study could impact Pfizer’s stock performance by providing valuable data on the effectiveness of its COVID-19 vaccine, potentially influencing market sentiment. As the study progresses, it may also affect the competitive landscape, particularly in the context of COVID-19 and influenza treatments and vaccines.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.